Market closedNon-fractional
Celldex/CLDX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Ticker
CLDX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Hampton, United States
Employees
160
Website
www.celldex.com
Celldex Metrics
BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$2.82
EPS
1.60
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
Beta
1.6
Financial strength
Current ratio
31.772
Quick ratio
31.437
Long term debt to equity
0.056
Total debt to equity
0.252
Management effectiveness
Return on assets (TTM)
-15.73%
Return on equity (TTM)
-25.39%
Valuation
Price to revenue (TTM)
303.77
Price to book
2.82
Price to tangible book (TTM)
2.91
Price to free cash flow (TTM)
-15.25
Growth
Revenue change (TTM)
92.76%
Earnings per share change (TTM)
11.76%
3-year revenue growth
4.15%
3-year earnings per share growth
15.88%
What the Analysts think about Celldex
Analyst Ratings
Majority rating from 8 analysts.
Celldex Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$100K
-97.56%
Net income
-$33M
-24.25%
Profit margin
-32,800.00%
3,005.80%
Celldex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.65
-$0.81
-$0.83
-$0.56
-
Expected
-$0.67
-$0.68
-$0.74
-$0.69
-$0.58
Surprise
-2.50%
19.37%
11.60%
-19.31%
-
Celldex News
AllArticlesVideos
Celldex Therapeutics to Present at Jefferies Healthcare Conference
GlobeNewsWire·4 weeks ago
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
GlobeNewsWire·1 month ago
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $2.4B as of July 05, 2024.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of July 05, 2024.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Celldex stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.